Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab with Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
NCT07200154Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Peking University Cancer Hospital & Institute. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07200154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07200154.